Drug developer PharmaEngine Inc (智擎生技) said its French partner Nanobiotix SA has received European market approval for PEP503 (NBTXR3), enabling commercialization of the nanoparticle radio-enhancer in the EU for the treatment of locally advanced soft-tissue sarcoma.
PEP503 would be marketed in the 27 EU countries under the brand name Hensify, PharmaEngine said in a filing with the Taiwan Stock Exchange on Saturday.
PharmaEngine in August 2012 acquired the exclusive rights from Nanobiotix to develop and commercialize PEP503 in the Asia-Pacific region.
PharmaEngine might be able to license the treatment to other companies in the region in the near term, the Chinese-language Commercial Times reported yesterday, adding that royalty revenue from sales could start from US$200 million.
PEP503 is a nanoparticle formulation of crystalline hafnium oxide that was designed to enhance the efficacy of radiotherapy for cancer treatment, the company said.
In addition to the treatment of soft-tissue sarcoma, PEP503 is being evaluated for other cancer types, such as head-and-neck cancer, liver cancer, rectal cancer and prostate cancer, PharmaEngine said.
In the US, the treatment has gained approval for a clinical trial in combination with anti-PD-1 immunotherapies for patients of non-small-cell lung cancer and head-and-neck cancer, the company said.
PharmaEngine reported cumulative revenue of NT$61.04 million (US$1.98 million) for the first two months of the year, up 96.29 percent from NT$31.1 million the previous year, a company regulatory filing showed.
The surge in revenue was mainly due to contributions from its pancreatic cancer drug, Onivyde, which has received reimbursements of NT$26,400 per vial from the National Health Insurance Administration since August last year.
The company posted net profit of NT$129.36 million for last year, or NT$0.88 in earnings per share, compared with the year-earlier level of NT$387.06 million, or NT$2.62 per share.
The US dollar was trading at NT$29.7 at 10am today on the Taipei Foreign Exchange, as the New Taiwan dollar gained NT$1.364 from the previous close last week. The NT dollar continued to rise today, after surging 3.07 percent on Friday. After opening at NT$30.91, the NT dollar gained more than NT$1 in just 15 minutes, briefly passing the NT$30 mark. Before the US Department of the Treasury's semi-annual currency report came out, expectations that the NT dollar would keep rising were already building. The NT dollar on Friday closed at NT$31.064, up by NT$0.953 — a 3.07 percent single-day gain. Today,
‘SHORT TERM’: The local currency would likely remain strong in the near term, driven by anticipated US trade pressure, capital inflows and expectations of a US Fed rate cut The US dollar is expected to fall below NT$30 in the near term, as traders anticipate increased pressure from Washington for Taiwan to allow the New Taiwan dollar to appreciate, Cathay United Bank (國泰世華銀行) chief economist Lin Chi-chao (林啟超) said. Following a sharp drop in the greenback against the NT dollar on Friday, Lin told the Central News Agency that the local currency is likely to remain strong in the short term, driven in part by market psychology surrounding anticipated US policy pressure. On Friday, the US dollar fell NT$0.953, or 3.07 percent, closing at NT$31.064 — its lowest level since Jan.
The New Taiwan dollar and Taiwanese stocks surged on signs that trade tensions between the world’s top two economies might start easing and as US tech earnings boosted the outlook of the nation’s semiconductor exports. The NT dollar strengthened as much as 3.8 percent versus the US dollar to 30.815, the biggest intraday gain since January 2011, closing at NT$31.064. The benchmark TAIEX jumped 2.73 percent to outperform the region’s equity gauges. Outlook for global trade improved after China said it is assessing possible trade talks with the US, providing a boost for the nation’s currency and shares. As the NT dollar
The Financial Supervisory Commission (FSC) yesterday met with some of the nation’s largest insurance companies as a skyrocketing New Taiwan dollar piles pressure on their hundreds of billions of dollars in US bond investments. The commission has asked some life insurance firms, among the biggest Asian holders of US debt, to discuss how the rapidly strengthening NT dollar has impacted their operations, people familiar with the matter said. The meeting took place as the NT dollar jumped as much as 5 percent yesterday, its biggest intraday gain in more than three decades. The local currency surged as exporters rushed to
RSS